The SGLT2 inhibitor dapagliflozin was associated with a reduced risk for hospitalization due to any cause in patients with chronic kidney disease with and without type 2 diabetes, according to a post hoc analysis of the DAPA-CKD trial. Read more in Healio.
Dapagliflozin reduces hospitalization risk in adults with chronic kidney disease
